Sharemaestro company-news research for Surrozen Inc (SRZN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest SRZN news and sentiment
Surrozen Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
10 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone79/100
→
Published 30-day score54/100
Latest source headline
Surrozen Is Maintained at Buy by HC Wainwright & Co.
Moomoo · 25 Sep 2026 19:56
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
10 current stories are mapped specifically to SRZN.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.141.
Confidence is 24/100, below the threshold for a firm score.
54/100
News scoreEarly balanced news score
24/100
Confidencethin evidence
78%/100
Company news10 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
31 Aug15 Sep29 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.141 after freshness weightingSource breadth40
2 independent publishersCompany relevance78
share tied directly to this companyFreshness40
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix50
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202656USD 29.54+78.5%
18 Sep 202650USD 16.55-12.9%
11 Sep 202650USD 19.0-16.5%
04 Sep 202651USD 22.76+1.5%
28 Aug 202652USD 22.42-6.5%
21 Aug 202657USD 23.99+0.1%
14 Aug 202655USD 23.96-6.5%
07 Aug 202656USD 25.62+15.4%
Provisional evidence
News subjects
What is shaping the score
Market update504 stories · 40%
Regulatory and legal503 stories · 30%
Analyst action722 stories · 20%
Guidance501 stories · 10%
Source mix
Where the evidence comes from
markets.businessinsider.com502 stories · 20%
Investing.com791 stories · 10%
Moomoo561 stories · 10%
www.mexc.co501 stories · 10%
TradingView501 stories · 10%
Glance by Eyes On Eyecare501 stories · 10%
Stock Traders Daily501 stories · 10%
Recurring subjects
Subjects appearing most often
Life Sciences7Financial Markets4Finance2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
19 Jun50 neutral28 Sep 03:27
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 28 Sep 03:27 | 54 | -2 | 26/100 (-7) | 10 (0) | Provisional |
| 25 Sep 23:59 | 56 | +6 | 33/100 (+19) | 10 (+2) | Provisional |
| 24 Sep 23:59 | 50 | +0 | 14/100 (0) | 8 (+1) | Provisional |
| 23 Sep 23:59 | 50 | +0 | 14/100 (-1) | 7 (-2) | Provisional |
| 16 Sep 23:59 | 50 | +0 | 15/100 (-1) | 9 (+1) | Provisional |
| 14 Sep 23:59 | 50 | +0 | 16/100 (-5) | 8 (-7) | Provisional |
| 09 Sep 23:59 | 50 | +0 | 21/100 (-4) | 15 (0) | Provisional |
| 08 Sep 23:59 | 50 | -1 | 25/100 (+8) | 15 (-8) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 10 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action1 story
0.0%100.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Analyst actionNot used in direction
Surrozen Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. has reiterated its Buy rating on Surrozen. This indicates a continued positive outlook from the analyst firm regarding the company's stock.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
HC Wainwright & Co. has reiterated its Buy rating on Surrozen. This indicates a continued positive outlook from the analyst firm regarding the company's stock.
- Published
- 25 Sep 2026 19:56
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Finance
79/100 tone
H.C. Wainwright increased its price target for Surrozen Inc. (NASDAQ:SRZN) to $54 from $44, maintaining a Buy rating, following positive Phase 2b/3 trial results from Merck for its Wnt pathway-targeting drug. This positive outcome validates the Wnt pathway approach, which H.C. Wainwright …
100% of directional evidence
High story strength
Scoring detailsDirect company coverage
H.C. Wainwright increased its price target for Surrozen Inc. (NASDAQ:SRZN) to $54 from $44, maintaining a Buy rating, following positive Phase 2b/3 trial results from Merck for its Wnt pathway-targeting drug. This positive outcome validates the Wnt pathway approach, which H.C. Wainwright believes provides read-through for Surrozen’s SZN-8141, a drug also targeting diabetic macular edema and expected to enter clinical trials by year-end 2026. Despite a recent stock surge, InvestingPro analysis suggests Surrozen's stock may be overvalued.
- Published
- 25 Sep 2026 12:56
- News subject
- Analyst action
- Why this score
- Analyst upgrade, Buy Rating, Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- High · 62/100
- 30-day weight
- 100% of directional evidence · 3.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
SRZN Price Today: Surrozen, Inc. Stock Price, Quote & Chart | MEXC
This article provides detailed information on Surrozen, Inc. (SRZN) stock, including its current pre-market price of $32.46, down 3.62%, and key market data such as market capitalization, trading volume, and 52-week price range. It also describes the company's operations as a clinical-sta…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides detailed information on Surrozen, Inc. (SRZN) stock, including its current pre-market price of $32.46, down 3.62%, and key market data such as market capitalization, trading volume, and 52-week price range. It also describes the company's operations as a clinical-stage biotechnology firm focused on modulating the Wnt pathway for tissue repair and offers instructions on how to buy SRZN stock on MEXC.
- Published
- 24 Sep 2026 19:24
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
SRZN Options Volatility — NASDAQ:SRZN
This article from TradingView provides an overview of options volatility for Surrozen, Inc. (SRZN) on the NASDAQ. It includes implied volatility curves for different expiration dates and ATM (at-the-money) implied volatility term structure, helping users assess market expectations and pot…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article from TradingView provides an overview of options volatility for Surrozen, Inc. (SRZN) on the NASDAQ. It includes implied volatility curves for different expiration dates and ATM (at-the-money) implied volatility term structure, helping users assess market expectations and potential trading opportunities. The information is presented to assist in crafting options strategies based on market sentiment.
- Published
- 23 Sep 2026 09:24
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Surrozen submits IND to FDA for DME therapeutic
Surrozen has submitted an Investigational New Drug (IND) application to the FDA for SZN-8141, a therapeutic intended for diabetic macular edema (DME). SZN-8141 is a bifunctional antibody that combines Wnt agonism with VEGF inhibition, aiming to address vascular leakage and promote retinal…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surrozen has submitted an Investigational New Drug (IND) application to the FDA for SZN-8141, a therapeutic intended for diabetic macular edema (DME). SZN-8141 is a bifunctional antibody that combines Wnt agonism with VEGF inhibition, aiming to address vascular leakage and promote retinal vascular integrity. The company plans to initiate a Phase 1b/2a clinical trial, DUET, by the end of 2026, with initial data expected in the second half of 2027.
- Published
- 16 Sep 2026 02:53
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
GuidanceNot used in direction
(SRZN) as a Liquidity Pulse for Institutional Tactics
This article analyzes Surrozen Inc. (NASDAQ: SRZN) using AI models to provide institutional trading strategies. It identifies weak near and mid-term sentiment but a strong long-term outlook for SRZN, with specific entry and exit points for position trading, momentum breakout, and risk hed…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article analyzes Surrozen Inc. (NASDAQ: SRZN) using AI models to provide institutional trading strategies. It identifies weak near and mid-term sentiment but a strong long-term outlook for SRZN, with specific entry and exit points for position trading, momentum breakout, and risk hedging strategies. The analysis highlights an elevated downside risk in the short term, lacking long-term support signals.
- Published
- 14 Sep 2026 20:28
- News subject
- Guidance
- Why this score
- Negative valuation view
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen, Inc. has submitted an Investigational New Drug (IND) application to the U.S. FDA for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema (DME). The company plans to initiate the DUET Phase 1b/2a clinical trial for DME pa…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surrozen, Inc. has submitted an Investigational New Drug (IND) application to the U.S. FDA for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema (DME). The company plans to initiate the DUET Phase 1b/2a clinical trial for DME patients by the end of 2026, with initial data expected in the second half of 2027. SZN-8141 aims to provide a differentiated approach by combining Wnt pathway activation and VEGF inhibition to address vascular leakage and promote retinal vascular integrity.
- Published
- 09 Sep 2026 09:26
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Life Sciences
—Unscored
Regulatory and legalNot used in direction
Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Sep 2026 14:40
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
One drug combines two approaches for diabetic vision loss. Surrozen submitted an application to the FDA.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Sep 2026 12:30
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Surrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen, Inc. (Nasdaq: SRZN) announced that its management will present at two upcoming healthcare investor conferences: the 2026 Cantor Global Healthcare Conference on September 10, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The company,…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surrozen, Inc. (Nasdaq: SRZN) announced that its management will present at two upcoming healthcare investor conferences: the 2026 Cantor Global Healthcare Conference on September 10, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The company, a biotechnology firm focused on Wnt signaling for ophthalmic conditions, will provide audio webcasts of these fireside chats on its investor relations website.
- Published
- 02 Sep 2026 20:33
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
Earlier company news
SRZN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 58 older SRZN headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to SRZN, but the headline and available text are not mainly about Surrozen Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of SRZN sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.